In the BioHarmony Drug Report Database

"Preview" Icon

Inebilizumab-cdon

Uplizna (inebilizumab) is an antibody pharmaceutical. Inebilizumab was first approved as Uplizna on 2020-06-11. It is used to treat neuromyelitis optica in the USA. The pharmaceutical is active against B-lymphocyte antigen CD19.

 

Trade Name

 

Uplizna
 

Common Name

 

inebilizumab
 

ChEMBL ID

 

CHEMBL2109334
 

Indication

 

neuromyelitis optica
 

Drug Class

 

Monoclonal antibodies: humanized, immunomodulating

Image (chem structure or protein)

Inebilizumab-cdon structure rendering